Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL. (Record no. 29165057)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 01989 a2200577 4500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250518013427.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 201909s 0 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
| International Standard Serial Number | 2473-9537 |
| 024 7# - OTHER STANDARD IDENTIFIER | |
| Standard number or code | 10.1182/bloodadvances.2018019422 |
| Source of number or code | doi |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | NLM |
| Language of cataloging | eng |
| Transcribing agency | NLM |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Kater, Arnon P |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 20190923 |
| 245 00 - TITLE STATEMENT | |
| Title | Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL. |
| Medium | [electronic resource] |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Name of publisher, distributor, etc. | Blood advances |
| Date of publication, distribution, etc. | 12 2018 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 3566-3571 p. |
| Other physical details | digital |
| 500 ## - GENERAL NOTE | |
| General note | Publication Type: Journal Article; Research Support, Non-U.S. Gov't |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Aged |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Antibodies, Monoclonal, Humanized |
| General subdivision | adverse effects |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Antineoplastic Agents |
| General subdivision | adverse effects |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Bridged Bicyclo Compounds, Heterocyclic |
| General subdivision | therapeutic use |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Drug Administration Schedule |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Drug Therapy, Combination |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Female |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Humans |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Leukemia, Lymphocytic, Chronic, B-Cell |
| General subdivision | drug therapy |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Male |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Middle Aged |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Neoplasm, Residual |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Remission Induction |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Risk Factors |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Sulfonamides |
| General subdivision | therapeutic use |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Tumor Lysis Syndrome |
| General subdivision | etiology |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Kersting, Sabina |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | van Norden, Yvette |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Dubois, Julie |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Dobber, Johan A |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Mellink, Clemens H |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Evers, Ludo M |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Croon-de Boer, Fransien |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Schreurs, John |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | van der Spek, Ellen |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Visser, Hein |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Idink, Cecile |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Wittebol, Shulamiet |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Hoogendoorn, Mels |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Tonino, Sanne H |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Mobasher, Mehrdad |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Levin, Mark-David |
| 773 0# - HOST ITEM ENTRY | |
| Title | Blood advances |
| Related parts | vol. 2 |
| -- | no. 24 |
| -- | p. 3566-3571 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://doi.org/10.1182/bloodadvances.2018019422">https://doi.org/10.1182/bloodadvances.2018019422</a> |
| Public note | Available from publisher's website |
No items available.